Fluxion Biosciences
A Cell Microsystems Company
A Cell Microsystems Company
Fluxion Biosciences is a leading, United States-based company in the Biopharma and Biotechnology industries. Acquired by Cell Microsystems, the company specializes in delivering cutting-edge solutions that automate complex assays. Their product line includes BioFlux, designed for functional analysis of cellular interactions under shear flow conditions, and the IonFlux automated patch clamp system. With a strong global presence, Fluxion has become the go-to choice for hundreds of labs worldwide, enabling them to conduct pioneering research and hasten the pace of drug discovery. In the latest investment round on 04 October 2019, Fluxion Biosciences secured a notable $280.00K grant from the National Institutes of Health. This investment is a testament to the company's innovative approach and its potential for further growth and development in the biotech sector.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Grant | $280.00K | 1 | National Institutes of Health | 04 Oct 2019 |
| Venture Round | $2.00M | 1 |
|
01 Oct 2012 |
| Series C | $12.00M | 3 |
|
09 Oct 2011 |
| Series B | $7.00M | 4 |
|
20 Oct 2007 |
| Grant | $1.20M | - | 17 May 2007 |
No recent news or press coverage available for Fluxion Biosciences.
We care about your data, and we'd love to use cookies make your experience better.
